Cargando…
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib
BACKGROUND: Soft tissue sarcomas (STS) are a rare type of malignancy comprising a variety of histological diagnoses. Chemotherapy constitutes the standard treatment for advanced STS. Doxorubicin-based regimens, which include the administration of doxorubicin alone or in combination with ifosfamide o...
Autores principales: | Endo, Makoto, Kataoka, Tomoko, Fujiwara, Toshifumi, Tsukushi, Satoshi, Takahashi, Masanobu, Kobayashi, Eisuke, Yamada, Yoko, Tanaka, Takaaki, Nezu, Yutaka, Hiraga, Hiroaki, Wasa, Junji, Nagano, Akihito, Nakano, Kenji, Nakayama, Robert, Hamada, Tetsuya, Kawano, Masanori, Torigoe, Tomoaki, Sakamoto, Akio, Asanuma, Kunihiro, Morii, Takeshi, Machida, Ryunosuke, Sekino, Yuta, Fukuda, Haruhiko, Oda, Yoshinao, Ozaki, Toshifumi, Tanaka, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996999/ https://www.ncbi.nlm.nih.gov/pubmed/36890471 http://dx.doi.org/10.1186/s12885-023-10693-w |
Ejemplares similares
-
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021) -
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017) -
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022) -
Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study
por: Urakawa, Hiroshi, et al.
Publicado: (2018) -
Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
por: Tamiya, Hironari, et al.
Publicado: (2020)